🔗 Share this article

A shadow market for unlicensed slimming medications is propelled by TikTok fitness influencers and vendors on messaging platforms, according to recent findings.

Experimental Drug Gaining Popularity Via Social Media

Retatrutide, which is still in research studies, is being advertised by social media influencers for its alleged fat-burning properties. Viewers are encouraged to contact these accounts directly for supplier links, while also obtaining promotional offers.

Active Commerce on Social Networks

Additionally, a robust market exists on messaging services, where groups with thousands of members share “before and after” photos, injection guides and claims of rapid British shipping. Sellers promote the substance there before redirecting customers to other platforms for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could help individuals lose up to 25% of their body weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic.

Healthcare Experts Voice Worries

Nevertheless, physicians and pharmacists have cautions that the distribution of what remains an unapproved medication in the United Kingdom is worrisome and could result in users injecting products of unknown origin.

Some professionals stated the demand for the experimental drug could be linked to the rising price of approved weight loss products such as Mounjaro.

Regulatory Status and Implementation

Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unapproved medication that cannot be promoted or distributed for human use under the British medical regulations.

Some content creators try to circumvent the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still violate pharmaceutical, marketing, and customer regulations, risking penalties, legal action or prison.

Service Response and Content Removal

Based on the social media company, the service has removed problematic content and prohibited associated keywords and query recommendations. The company stated it was committed to maintaining the service secure and allocating resources in enhancing enforcement strategies.

Online Trading Operations

Research also found groups with up to nine thousand members selling the experimental drug using the platform's built-in search feature, which operates like a online catalog. Typing “retatrutide” immediately displays groups with numerous of members, populated with photos of weight loss, glowing testimonials and detailed instructions for preparing or injecting at home.

After moments of joining one community, a vendor posted contact information, where the majority of transactions take place. The vendor provided an guidebook and guaranteed delivery within two days. When questioned whether the product was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one asked about weight, medical conditions or past usage.

Product Information and Pricing

Within these communities, posts show dark colored packages with Royal Mail labels, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at home with purified liquid, or pre-filled injectors typically sold at £160 for 20mg. When questioned how long a pen should be used, sellers give conflicting responses varying between a several days to “depends on your body”.

Platform Oversight and Safety Actions

A representative for Telegram said it actively moderated harmful material on its service including content that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Warnings

“Individuals are injecting materials they cannot confirm. Even if the research behind this drug is valid, these digital products may not contain what they advertise,” said a pharmacy expert, the head of pharmaceutical services at a pharmacy service.

A medical professional of Asda Online Doctor connected the surge in interest to recent cost increases for authorized slimming drugs such as Mounjaro. “With prices rising, patients are using social media. But counterfeit treatments are extremely risky. You cannot know what’s contained or whether the conditions they were made in was clean,” she said.

Her staff has already seen patients injured by self-injection from unconfirmed sources. “We recognize the disappointment, but buying from messaging apps or WhatsApp is gambling with your health,” said the doctor. “These substances could be impure or incorrectly dosed.”

Manufacturer Statement

A spokesperson from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Therefore at this point no one can market [it] for human use,” they said, noting that any item “misleadingly claiming itself as a Lilly investigational substance not yet approved … may expose patients to possibly significant medical dangers”.